{"hands_on_practices": [{"introduction": "The primary objective of damage control resuscitation is to restore adequate oxygen delivery ($DO_2$) to vital organs, arresting the downward spiral of shock. This practice problem focuses on quantifying the direct impact of red blood cell transfusion on $DO_2$, moving beyond the simple metric of hemoglobin concentration to a more holistic physiological understanding. Calculating the change in oxygen delivery reinforces the fundamental principles of oxygen transport and the rationale for blood product administration in hemorrhagic shock [@problem_id:4596821].", "problem": "A patient in hemorrhagic shock is undergoing Advanced Damage Control Resuscitation in the operating room. You are informed that the pretransfusion cardiac output (CO) is $5$ L/min measured by thermodilution, the hemoglobin (Hb) concentration is $8$ g/dL, the arterial oxygen saturation (SaO$_2$) is $0.95$, and the arterial oxygen partial pressure (PaO$_2$) is $80$ mmHg on stable ventilator settings. Two units of red blood cells (RBCs) are transfused, and you may assume that Hb increases to $10$ g/dL and that CO remains constant during this interval. Using only the following foundational facts:\n- Oxygen is carried in arterial blood bound to hemoglobin and dissolved in plasma.\n- Each gram of hemoglobin binds approximately $1.34$ mL of oxygen when fully saturated.\n- Dissolved oxygen content is approximately $0.0031$ mL/dL per mmHg of PaO$_2$.\n- There are $10$ deciliters in $1$ liter.\n\nCompute the baseline systemic oxygen delivery, $DO_2$, and the expected change in $DO_2$ after the transfusion (defined as posttransfusion $DO_2$ minus pretransfusion $DO_2$). Express both answers in mL O$_2$/min. Round your answers to four significant figures. Provide your final numerical answers as two values in a single row matrix in the order baseline $DO_2$, change in $DO_2$.", "solution": "The problem is valid as it is scientifically grounded in established physiological principles, is well-posed with sufficient and consistent data, and is expressed in objective, formal language. We can proceed with the calculation.\n\nSystemic oxygen delivery, denoted as $DO_2$, is the total amount of oxygen delivered to the peripheral tissues per unit time. It is a critical parameter in physiology and critical care medicine. The governing equation for $DO_2$ is the product of the cardiac output ($CO$) and the arterial oxygen content ($CaO_2$):\n$$DO_2 = CO \\times CaO_2$$\nTo calculate $DO_2$, we must first determine the arterial oxygen content, $CaO_2$.\n\nThe total oxygen content in arterial blood, $CaO_2$, is the sum of two components: oxygen chemically bound to hemoglobin and oxygen physically dissolved in the plasma. The formula for $CaO_2$ is:\n$$CaO_2 = (Hb \\times k_{Hb} \\times SaO_2) + (PaO_2 \\times k_{diss})$$\nwhere:\n- $Hb$ is the hemoglobin concentration in g/dL.\n- $k_{Hb}$ is the oxygen-binding capacity of hemoglobin, given as $1.34$ mL O$_2$ per gram of $Hb$.\n- $SaO_2$ is the arterial oxygen saturation, representing the fraction of hemoglobin saturated with oxygen.\n- $PaO_2$ is the partial pressure of oxygen in arterial blood, in mmHg.\n- $k_{diss}$ is the solubility coefficient of oxygen in plasma, given as $0.0031$ mL O$_2$ per dL of blood per mmHg of $PaO_2$.\n\nThe units of $CaO_2$ resulting from this formula are mL O$_2$/dL. The cardiac output, $CO$, is given in L/min. To ensure dimensional consistency, we must convert the units of $CO$ from L/min to dL/min, using the provided conversion factor $1$ L $= 10$ dL.\n$$CO \\text{ (in dL/min)} = CO \\text{ (in L/min)} \\times 10 \\frac{\\text{dL}}{\\text{L}}$$\n\nFirst, we will calculate the baseline (pretransfusion) systemic oxygen delivery, $DO_{2, \\text{pre}}$.\n\nThe given pretransfusion values are:\n- $CO = 5$ L/min\n- $Hb_{\\text{pre}} = 8$ g/dL\n- $SaO_2 = 0.95$\n- $PaO_2 = 80$ mmHg\n\nStep 1: Calculate the baseline arterial oxygen content, $CaO_{2, \\text{pre}}$.\n$$CaO_{2, \\text{pre}} = (Hb_{\\text{pre}} \\times k_{Hb} \\times SaO_2) + (PaO_2 \\times k_{diss})$$\nSubstituting the given values:\n$$CaO_{2, \\text{pre}} = (8 \\text{ g/dL} \\times 1.34 \\frac{\\text{mL O}_2}{\\text{g}} \\times 0.95) + (80 \\text{ mmHg} \\times 0.0031 \\frac{\\text{mL O}_2}{\\text{dL} \\cdot \\text{mmHg}})$$\n$$CaO_{2, \\text{pre}} = (10.184) + (0.248) \\frac{\\text{mL O}_2}{\\text{dL}}$$\n$$CaO_{2, \\text{pre}} = 10.432 \\frac{\\text{mL O}_2}{\\text{dL}}$$\n\nStep 2: Calculate the baseline systemic oxygen delivery, $DO_{2, \\text{pre}}$.\nFirst, convert cardiac output to dL/min:\n$$CO = 5 \\frac{\\text{L}}{\\text{min}} \\times 10 \\frac{\\text{dL}}{\\text{L}} = 50 \\frac{\\text{dL}}{\\text{min}}$$\nNow, calculate $DO_{2, \\text{pre}}$:\n$$DO_{2, \\text{pre}} = CO \\times CaO_{2, \\text{pre}}$$\n$$DO_{2, \\text{pre}} = 50 \\frac{\\text{dL}}{\\text{min}} \\times 10.432 \\frac{\\text{mL O}_2}{\\text{dL}}$$\n$$DO_{2, \\text{pre}} = 521.6 \\frac{\\text{mL O}_2}{\\text{min}}$$\nRounding to four significant figures, the baseline $DO_2$ is $521.6$ mL O$_2$/min.\n\nNext, we calculate the change in oxygen delivery, $\\Delta DO_2$, after the transfusion.\nThe posttransfusion hemoglobin level is given as $Hb_{\\text{post}} = 10$ g/dL. The problem states that cardiac output remains constant ($CO = 50$ dL/min), and we assume other parameters ($SaO_2$ and $PaO_2$) also remain constant as the patient is on stable ventilator settings.\n\nThe change in $DO_2$ is given by:\n$$\\Delta DO_2 = DO_{2, \\text{post}} - DO_{2, \\text{pre}}$$\n$$\\Delta DO_2 = (CO \\times CaO_{2, \\text{post}}) - (CO \\times CaO_{2, \\text{pre}})$$\n$$\\Delta DO_2 = CO \\times (CaO_{2, \\text{post}} - CaO_{2, \\text{pre}})$$\nThe change in arterial oxygen content, $\\Delta CaO_2$, is due only to the change in hemoglobin concentration, as other factors are constant:\n$$\\Delta CaO_2 = [(Hb_{\\text{post}} \\times k_{Hb} \\times SaO_2) + (PaO_2 \\times k_{diss})] - [(Hb_{\\text{pre}} \\times k_{Hb} \\times SaO_2) + (PaO_2 \\times k_{diss})]$$\n$$\\Delta CaO_2 = (Hb_{\\text{post}} - Hb_{\\text{pre}}) \\times k_{Hb} \\times SaO_2$$\nSubstituting the values:\n$$\\Delta CaO_2 = (10 \\text{ g/dL} - 8 \\text{ g/dL}) \\times 1.34 \\frac{\\text{mL O}_2}{\\text{g}} \\times 0.95$$\n$$\\Delta CaO_2 = 2 \\text{ g/dL} \\times 1.34 \\frac{\\text{mL O}_2}{\\text{g}} \\times 0.95$$\n$$\\Delta CaO_2 = 2.546 \\frac{\\text{mL O}_2}{\\text{dL}}$$\n\nNow, we can calculate the change in systemic oxygen delivery, $\\Delta DO_2$:\n$$\\Delta DO_2 = CO \\times \\Delta CaO_2$$\n$$\\Delta DO_2 = 50 \\frac{\\text{dL}}{\\text{min}} \\times 2.546 \\frac{\\text{mL O}_2}{\\text{dL}}$$\n$$\\Delta DO_2 = 127.3 \\frac{\\text{mL O}_2}{\\text{min}}$$\nRounding to four significant figures, the change in $DO_2$ is $127.3$ mL O$_2$/min.\n\nThe two requested values are the baseline systemic oxygen delivery, $DO_{2, \\text{pre}}$, and the change in systemic oxygen delivery, $\\Delta DO_2$.\n- Baseline $DO_2$: $521.6$ mL O$_2$/min\n- Change in $DO_2$: $127.3$ mL O$_2$/min", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n521.6  127.3\n\\end{pmatrix}\n}\n$$", "id": "4596821"}, {"introduction": "Effective hemostasis depends on a robust fibrin clot, and severe trauma often leads to critical hypofibrinogenemia that must be corrected swiftly. This exercise challenges you to perform a goal-directed dosing calculation for fibrinogen replacement, a cornerstone of modern massive transfusion protocols. By determining the precise dose required to reach a target concentration, you will practice the quantitative skills necessary for effective, evidence-based management of trauma-induced coagulopathy [@problem_id:4596949].", "problem": "An adult trauma patient of body mass $80\\ \\mathrm{kg}$ arrives in hemorrhagic shock on an Advanced Damage Control Resuscitation (DCR) strategy within a Massive Transfusion Protocol (MTP). Laboratory testing shows a Clauss fibrinogen of $120\\ \\mathrm{mg/dL}$ and a hematocrit of $0.40$. The resuscitation goal is to achieve a fibrinogen concentration of $250\\ \\mathrm{mg/dL}$ as rapidly as possible to support hemostasis.\n\nUse first principles of mass conservation and the definition of concentration to compute the fibrinogen dose required to raise the plasma fibrinogen from $120\\ \\mathrm{mg/dL}$ to $250\\ \\mathrm{mg/dL}$. Assume the following well-established physiological and product characteristics:\n\n- Typical adult blood volume is $70\\ \\mathrm{mL/kg}$.\n- Plasma volume equals blood volume multiplied by one minus the hematocrit.\n- In vivo recovery (the fraction of administered fibrinogen that appears in the intravascular space as measurable fibrinogen immediately after infusion in a bleeding trauma patient) is $0.80$ for both fibrinogen concentrate and cryoprecipitate.\n- One cryoprecipitate “pool” consists of $5$ single-donor units; each unit contains $250\\ \\mathrm{mg}$ of fibrinogen, for a total of $1{,}250\\ \\mathrm{mg}$ fibrinogen per pool.\n\nCompute and report two quantities:\n- The fibrinogen concentrate dose required to reach the target, expressed in grams.\n- The number of cryoprecipitate pools required, expressed as a whole number of pools.\n\nRound the fibrinogen concentrate dose to three significant figures. For the cryoprecipitate pools, report the smallest integer number of pools that meets or exceeds the calculated requirement. In your reasoning, briefly outline timing considerations in DCR for selecting between fibrinogen concentrate and cryoprecipitate, but ensure the final reported answer is only the two requested quantities. No other outputs are permitted.", "solution": "The problem is assessed to be valid as it is scientifically grounded in established physiological and pharmacological principles, well-posed with sufficient and consistent data, and objective in its formulation. The problem requires the application of first principles of mass conservation and concentration to a clinically relevant scenario in trauma resuscitation.\n\nWe begin by defining the variables provided in the problem statement:\n- Patient body mass, $m = 80\\ \\mathrm{kg}$\n- Specific blood volume, $v_{blood} = 70\\ \\mathrm{mL/kg}$\n- Initial hematocrit, $Hct = 0.40$\n- Initial fibrinogen concentration, $C_{initial} = 120\\ \\mathrm{mg/dL}$\n- Target fibrinogen concentration, $C_{target} = 250\\ \\mathrm{mg/dL}$\n- In vivo recovery factor, $R_{iv} = 0.80$\n- Fibrinogen content per cryoprecipitate pool, $M_{pool} = 1250\\ \\mathrm{mg}$\n\nOur first step is to calculate the patient's plasma volume, which is the volume of distribution for fibrinogen. First, we determine the total blood volume ($V_{blood}$).\n$$V_{blood} = m \\times v_{blood}$$\n$$V_{blood} = 80\\ \\mathrm{kg} \\times 70\\ \\frac{\\mathrm{mL}}{\\mathrm{kg}} = 5600\\ \\mathrm{mL}$$\nSince concentrations are given in milligrams per deciliter ($\\mathrm{mg/dL}$), we convert the volume to deciliters. Given that $1\\ \\mathrm{L} = 10\\ \\mathrm{dL}$ and $1\\ \\mathrm{L} = 1000\\ \\mathrm{mL}$, we have:\n$$V_{blood} = 5600\\ \\mathrm{mL} = 5.6\\ \\mathrm{L} = 56\\ \\mathrm{dL}$$\nNext, we calculate the plasma volume ($V_{plasma}$) using the provided formula, which accounts for the volume occupied by red blood cells (defined by the hematocrit).\n$$V_{plasma} = V_{blood} \\times (1 - Hct)$$\n$$V_{plasma} = 56\\ \\mathrm{dL} \\times (1 - 0.40) = 56\\ \\mathrm{dL} \\times 0.60 = 33.6\\ \\mathrm{dL}$$\n\nThe second step is to determine the total mass of fibrinogen required to increase the concentration in the plasma from the initial to the target level. This is the fibrinogen mass deficit, which we denote as $\\Delta M_{fib}$.\n$$\\Delta M_{fib} = (C_{target} - C_{initial}) \\times V_{plasma}$$\n$$\\Delta M_{fib} = \\left(250\\ \\frac{\\mathrm{mg}}{\\mathrm{dL}} - 120\\ \\frac{\\mathrm{mg}}{\\mathrm{dL}}\\right) \\times 33.6\\ \\mathrm{dL}$$\n$$\\Delta M_{fib} = 130\\ \\frac{\\mathrm{mg}}{\\mathrm{dL}} \\times 33.6\\ \\mathrm{dL} = 4368\\ \\mathrm{mg}$$\nThis value, $4368\\ \\mathrm{mg}$, represents the net increase in intravascular fibrinogen mass required to achieve the target concentration.\n\nThe third step is to calculate the actual dose that must be administered. The problem specifies an in vivo recovery ($R_{iv}$) of $0.80$, meaning only $80\\%$ of the administered dose becomes available in the plasma. Therefore, the required administered dose ($D_{req}$) must be greater than the mass deficit.\n$$D_{req} = \\frac{\\Delta M_{fib}}{R_{iv}}$$\n$$D_{req} = \\frac{4368\\ \\mathrm{mg}}{0.80} = 5460\\ \\mathrm{mg}$$\n\nNow we can compute the two requested quantities.\n\n1.  **Fibrinogen concentrate dose in grams:**\n    The total required dose is $5460\\ \\mathrm{mg}$. To convert this to grams, we divide by $1000$.\n    $$D_{req} (\\mathrm{g}) = \\frac{5460\\ \\mathrm{mg}}{1000\\ \\mathrm{mg/g}} = 5.460\\ \\mathrm{g}$$\n    The problem requests this value rounded to three significant figures, which is $5.46\\ \\mathrm{g}$.\n\n2.  **Number of cryoprecipitate pools:**\n    Each pool of cryoprecipitate provides $M_{pool} = 1250\\ \\mathrm{mg}$ of fibrinogen. To find the number of pools ($N_{pools}$) needed, we divide the total required dose by the amount per pool.\n    $$N_{pools} = \\frac{D_{req}}{M_{pool}}$$\n    $$N_{pools} = \\frac{5460\\ \\mathrm{mg}}{1250\\ \\mathrm{mg/pool}} = 4.368\\ \\mathrm{pools}$$\n    Since cryoprecipitate is administered in whole pools, we must use the smallest integer number of pools that meets or exceeds the calculated requirement. This corresponds to taking the ceiling of the calculated value.\n    $$N_{pools, final} = \\lceil 4.368 \\rceil = 5$$\n    Therefore, $5$ pools of cryoprecipitate are required.\n\nFinally, regarding timing considerations in Damage Control Resuscitation (DCR), the primary factor distinguishing fibrinogen concentrate from cryoprecipitate is the speed of availability. Fibrinogen concentrate is a lyophilized powder that can be reconstituted with sterile water and administered in minutes. It is stored at room temperature and allows for precise high-concentration dosing in a small volume. In contrast, cryoprecipitate is a frozen blood product that requires thawing in a specialized water bath, a process that can take $15-30$ minutes. Subsequently, individual units must be pooled under sterile conditions, adding further delay. In the context of exsanguinating hemorrhage where time is critical, the rapid availability and administration of fibrinogen concentrate make it a superior choice for quickly correcting severe hypofibrinogenemia, provided it is available and included in the institution's protocol.", "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n5.46  5\n\\end{pmatrix}\n}\n$$", "id": "4596949"}, {"introduction": "The fibrinolytic system plays a dual role in trauma, with both excessive activity (hyperfibrinolysis) and suppression (shutdown) linked to poor outcomes. This practice problem hones your ability to use viscoelastic testing to diagnose these distinct phenotypes and make critical therapeutic decisions regarding antifibrinolytic therapy. Correctly interpreting these patterns is essential for the safe and effective administration of agents like tranexamic acid (TXA) within a modern DCR framework [@problem_id:4596995].", "problem": "A severely injured adult in hemorrhagic shock undergoes early viscoelastic assessment during damage control resuscitation. You are provided two tracings to interpret. Use the foundational facts that: (i) fibrinolysis is plasmin-mediated degradation of fibrin, driven by tissue plasminogen activator and inhibited by plasminogen activator inhibitor-$1$; (ii) tranexamic acid (TXA) is a lysine analogue that competitively inhibits plasminogen binding to fibrin, thereby reducing plasmin generation on the fibrin surface; and (iii) thromboelastography (TEG) and rotational thromboelastometry (ROTEM) report clot strength as an amplitude $A(t)$ over time and report fibrinolysis as a percentage decrease in amplitude after reaching peak clot strength. No additional formulas are provided.\n\nTwo viscoelastic results, each obtained within $60$ minutes of injury and during active massive transfusion, are shown:\n\n- Trace X (TEG and ROTEM):\n  - TEG maximum amplitude (MA): $62$ mm.\n  - TEG amplitude $30$ minutes after MA: $61.7$ mm.\n  - ROTEM EXTEM maximum lysis (ML): $1\\%$.\n- Trace Y (TEG and ROTEM):\n  - TEG maximum amplitude (MA): $58$ mm.\n  - TEG amplitude $30$ minutes after MA: $48$ mm.\n  - ROTEM EXTEM maximum lysis (ML): $22\\%$.\n\nAssume the patient remains hemodynamically unstable and is receiving balanced blood products as part of a massive transfusion protocol (MTP), along with calcium and temperature correction. Based on first principles of fibrin polymerization and fibrinolysis and well-established clinical evidence on TXA timing in trauma, which of the following statements are most appropriate? Select all that apply.\n\nA. Trace X demonstrates fibrinolysis shutdown; TXA should be avoided, and resuscitation should focus on balanced components and correction of hypoperfusion without antifibrinolytic therapy, given concern for venous thromboembolism if antifibrinolysis is augmented in shutdown.\n\nB. Trace Y demonstrates pathologic hyperfibrinolysis; TXA is indicated as early as possible and within $3$ hours of injury as part of hemorrhage control in the massive transfusion protocol.\n\nC. Both traces reflect physiologic fibrinolysis and should not trigger TXA; TXA should only be considered if the TEG $30$-minute lysis exceeds $30\\%$.\n\nD. Trace X indicates impaired fibrin formation rather than fibrinolysis abnormality, so TXA is indicated; fibrinogen supplementation should be deferred.\n\nE. In the absence of viscoelastic testing, empiric TXA administered after $4$ hours of injury still confers mortality benefit and is indicated for both traces.", "solution": "Begin from the physiological and measurement bases. Fibrinolysis is the process by which plasmin degrades fibrin. Tranexamic acid (TXA) inhibits plasminogen-fibrin binding, reducing plasmin generation on the clot surface. Thromboelastography (TEG) and rotational thromboelastometry (ROTEM) quantify the viscoelastic behavior of clot as amplitude $A(t)$ over time. After the clot reaches its peak strength (maximum amplitude, MA), the fractional loss of amplitude over a defined interval reflects fibrinolytic activity. On TEG, the $30$-minute lysis (LY$30$) is the percentage decrease in amplitude $30$ minutes after MA relative to MA. On ROTEM, maximum lysis (ML) is the maximal percent decrease from the peak amplitude during the observation window. Trauma literature commonly stratifies lysis phenotypes (using TEG) as: fibrinolysis shutdown when $LY30  0.8\\%$, physiologic fibrinolysis when $LY30$ is approximately $0.8-3\\%$, and hyperfibrinolysis when $LY30 \\ge 3\\%$. On ROTEM EXTEM, ML substantially elevated (for example, $> 15\\%$) supports hyperfibrinolysis; very low ML approximating $0-1\\%$ supports shutdown.\n\nCompute the TEG LY$30$ for each trace from the provided amplitudes using the definition of percentage change relative to the peak.\n\n- Trace X:\n  - MA $=62$ mm, amplitude at $30$ minutes after MA $=61.7$ mm.\n  - Absolute decrease $=62-61.7=0.3$ mm.\n  - Fractional decrease $=0.3/62 \\approx 0.00484$.\n  - $LY30 \\approx 0.484\\%$, which is $ 0.8\\%$, consistent with fibrinolysis shutdown. ROTEM EXTEM ML $=1\\%$ corroborates minimal lysis.\n  - Pathophysiology: elevated Plasminogen Activator Inhibitor-1 and hypoperfusion-mediated antifibrinolytic dominance can produce shutdown. Augmenting antifibrinolysis with TXA when fibrinolysis is already suppressed risks tipping toward microvascular thrombosis and venous thromboembolism without hemorrhage control benefit.\n  - Clinical implication: avoid TXA; continue balanced products, correct hypoperfusion, and address other deficits (for example, fibrinogen if low, platelets if low), but not antifibrinolytics in shutdown.\n\n- Trace Y:\n  - MA $=58$ mm, amplitude at $30$ minutes after MA $=48$ mm.\n  - Absolute decrease $=58-48=10$ mm.\n  - Fractional decrease $=10/58 \\approx 0.1724$.\n  - $LY30 \\approx 17.24\\%$, which is $\\ge 3\\%$, indicating marked hyperfibrinolysis. ROTEM EXTEM ML $=22\\%$ is substantially elevated, supporting hyperfibrinolysis.\n  - Pathophysiology: excess tissue plasminogen activator and unopposed plasmin activity degrade fibrin rapidly, leading to clot failure.\n  - Clinical implication: TXA is indicated as early as possible and within $3$ hours of injury based on well-tested clinical evidence (for example, the CRASH-2 trial), with benefit greatest when given early and potential harm when given beyond $3$ hours.\n\nNow analyze each option:\n\nA. This states that Trace X is fibrinolysis shutdown and recommends avoiding TXA while focusing on balanced resuscitation. Our calculation showed $LY30 \\approx 0.484\\%$ with EXTEM ML $=1\\%$, consistent with shutdown. Avoidance of TXA in shutdown is supported by pathophysiology and observational data linking shutdown to thrombotic risk when antifibrinolysis is further augmented. Verdict: Correct.\n\nB. This states that Trace Y is pathologic hyperfibrinolysis and recommends early TXA within $3$ hours. Our calculation showed $LY30 \\approx 17.24\\%$ and EXTEM ML $=22\\%$, consistent with hyperfibrinolysis. Early TXA (within $3$ hours, ideally as soon as possible) is indicated in bleeding trauma with hyperfibrinolysis. Verdict: Correct.\n\nC. This claims both traces are physiologic and sets a TXA threshold of LY$30>30\\%$. Trace X is shutdown, not physiologic; Trace Y is severe hyperfibrinolysis. A threshold of $30\\%$ for TXA is inappropriately high; hyperfibrinolysis is generally recognized at $LY30\\ge 3\\%$. Verdict: Incorrect.\n\nD. This asserts Trace X shows impaired fibrin formation and indicates TXA, with deferral of fibrinogen supplementation. Trace X shows minimal lysis, not inherently impaired fibrin formation, and TXA is not indicated. Moreover, fibrinogen replacement decisions should be guided by fibrinogen assays or fibrin-specific viscoelastic parameters, not by suppressing fibrinolysis; deferring fibrinogen purely based on these lysis values is inappropriate. Verdict: Incorrect.\n\nE. This suggests empiric TXA after $4$ hours still confers mortality benefit and is indicated for both. Large randomized evidence indicates that TXA administered beyond $3$ hours after injury is associated with increased mortality in bleeding trauma patients. Therefore, recommending TXA after $4$ hours is inappropriate; additionally, Trace X represents shutdown where TXA should be avoided. Verdict: Incorrect.\n\nTherefore, the correct choices are A and B.", "answer": "$$\\boxed{AB}$$", "id": "4596995"}]}